IDO1 and neoplasm: Its key rate-limiting enzymes, indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO), are highly expressed in various tumors, leading to tryptophan depletion and the accumulation of metabolites such as kynurenine in the tumor microenvironment (133).